纤维细胞生长因子受体抑制剂降低黑色素瘤细胞系的增殖,其活性由维生素D调节
Anna Piotrowska1, Joanna I Nowak1, Justyna M Wierzbicka1
1Faculty of Medicine, Department of Histology, Medical University of Gdańsk, Dębinki 1a, 80-384 Gdańsk, Poland.
International journal of molecular sciences
|March 13, 2024
概括
维生素D增强了新型纤维细胞生长因子受体 (FGFR) 抑制剂,如CPL304110,对黑色素瘤细胞的疗效. 这种维生素D和FGFR抑制剂的组合显示出未来黑色素瘤治疗策略的潜力.
科学领域:
- 在瘤学瘤学.
- 皮肤病学 皮肤病学
- 分子生物学分子生物学
背景情况:
- 恶性黑色素瘤仍然是致命的皮肤癌,尽管治疗进展.
- 维生素D及其类似物以前已被证明可以增强抗癌药物的活性.
- 纤维细胞生长因子受体 (FGFRs) 与癌症进展有关.
研究的目的:
- 研究新型FGFR抑制剂CPL304110的疗效,并将其与黑色素瘤细胞系中的AZD4547进行比较.
- 为了确定1,25(OH) 2D3是否调节黑色素瘤细胞对这些FGFR抑制剂的反应.
- 探索维生素D信号传递和黑色素瘤中的FGFR抑制剂活性之间的相互作用.
主要方法:
- 用CPL304110和AZD4547.7治疗A375和RPMI7951黑色素瘤细胞系.
- 评估细胞活力,细胞循环停止和细胞亡/亡.
- 评估1,25(OH) 2D3对药物疗效和信号通路的影响.
- 对FGFR表达和酸化的分析.
主要成果:
- CPL304110 证明了黑色素瘤细胞活力的强烈抑制 (IC50 < 1μM).
- 1,25(OH) 2D3在A375细胞中显著增强了CPL304110的疗效,但在RPMI7951细胞中没有.
- 根据细胞系,FGFR抑制剂诱导细胞循环停止或细胞亡.
- 观察到维生素D信号传递和FGFR抑制剂活性之间的细胞特异交叉.
结论:
- 新型FGFR抑制剂CPL304110对黑色素瘤细胞有效.
- 维生素D可以以细胞特异的方式增强FGFR抑制剂的抗黑色素瘤作用.
- 维生素D途径和FGFR抑制剂之间的相互作用需要进一步研究,以便在黑色素瘤治疗中临床应用.
相关概念视频
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
TGF - β Signaling Pathway
7.3K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K


